Impact of Gene Expression Classifier Testing on Adjuvant Treatment Following Radical Prostatectomy – APCC

Advanced Prostate Cancer Consensus Conference (APCC) recently shared a study about the Impact of Gene Expression Classifier Testing on Adjuvant Treatment Following Radical Prostatectomy. Read the post on LinkedIn below:

“Impact of Gene Expression Classifier Testing on Adjuvant Treatment Following Radical Prostatectomy: The G-MINOR Prospective Randomized Cluster-crossover Trial out on EU platinum by Todd M. Morgan, MD and team.

This study assessed the impact of the Decipher genomic classifier (GC) on decisions regarding adjuvant therapy after radical prostatectomy (RP) in patients with high-risk prostate cancer.

Conducted as a randomized cluster-crossover trial, patients at multiple centers either received GC-informed care or usual care (UC).

Results showed that while the GC did influence treatment decisions, particularly in patients with high-risk GC scores, the overall difference in adjuvant treatment rates between the GC and UC arms was small (0.99%) and not statistically significant.

Higher GC risk was associated with significantly greater odds of receiving adjuvant therapy, but there was no difference in patient-reported urinary or sexual function between groups.

The study could not yet confirm any oncologic benefits from GC-guided therapy.”

More posts featuring APCC.